News
Our latest news, announcements and multimedia resources
Latest News
Conjustar announced the completion of ￥100 million Pre-A+ round of financing. This round of financing was led by Fosun health Capital New Drug Innovation Fund of Fosun Pharmaceutical, and co-invested by Hengqin Venture Capital and Shenzhen Qianhai Liyuan.
On August 8, 2024, Conjustar Biologics announced that the investigational new drug (IND) application for the company's second peptide-drug conjugate (PDC), SC-102 for Injection, for the treatment of advanced malignant solid tumors expressing EphA2, was approved by the Center for Drug Evaluation (CDE) of the Chinese National Medical Products Administration.
On May 31, 2024, Conjustar Biologics announced that its Nectin-4 targeting PDC drug SC-101 has received Investigational New Drug (IND) approval from the U.S. Food and Drug.
First in China: the Phase Ⅰ FIH study of SC-101, a Nectin-4-targeting Peptide Drug Conjugate (PDC), has been approved by the Chinese National Medical Products Administration.
Clinical stage, novel peptide-drug conjugates (PDCs) and nanobody-drug conjugates (NDCs) with BIC/FIC potential for challenge target in oncology.
About Us
R&D and Products
Contact Us
Tel: 021-33670826
E-mail: Info@conjustar.com
Add: 3rd Floor, Building 2, 367 Shengrong Road, Pudong New Area, Shanghai
